Latest news with #pipeline
Globe and Mail
2 hours ago
- Business
- Globe and Mail
Type 2 Diabetes Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
DelveInsight's, 'Type 2 Diabetes Pipeline Insight, 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Type 2 Diabetes pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 2 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Type 2 Diabetes Research. Learn more about our innovative pipeline today! @ Type 2 Diabetes Pipeline Outlook Key Takeaways from the Type 2 Diabetes Pipeline Report In July 2025, AstraZeneca announced a Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy. In July 2025, Novo Nordisk A/S conducted a study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. In July 2025, Sanofi organized a Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA. In July 2025, Getz Pharma announced a study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population. DelveInsight's Type 2 Diabetes pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Type 2 Diabetes treatment. The leading Type 2 Diabetes Companies such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others. Promising Type 2 Diabetes Pipeline Therapies such as Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea and others. Stay informed about the cutting-edge advancements in Type 2 Diabetes treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ Type 2 Diabetes Clinical Trials Assessment Type 2 Diabetes Emerging Drugs Profile LY-3209590: Eli Lilly and Company Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes. THDB0206: Tonghua Dongbao Pharmaceutical BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of type 2 diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Type 2 Diabetes. HU6: Rivus Pharmaceuticals Rivus Pharmaceuticals is developing HU6, a novel oral medication classified as a Controlled Metabolic Accelerator (CMA), aimed at treating various metabolic diseases, including type 2 diabetes. HU6 works by leveraging mitochondrial uncoupling to increase the body's resting metabolic rate, promoting fat loss while preserving lean muscle mass. Currently, the drug is in the Phase II stage of development to treat Type 2 Diabetes. AZD-5004, also known as ECC5004, is an investigational small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by AstraZeneca in collaboration with Eccogene. It is primarily aimed at treating obesity, type 2 diabetes, and related cardiometabolic conditions. AZD-5004 works by mimicking the effects of GLP-1, a hormone that regulates appetite and insulin secretion. This mechanism is crucial for managing weight and improving glucose metabolism, making it a potential therapeutic option for individuals with obesity and type 2 diabetes. Currently, the drug is in the Phase II stage of development to treat Type 2 Diabetes. XW014: Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and type 2 diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes. KN056: Suzhou Alphamab Co., Ltd. KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. for the treatment of type 2 diabetes. KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor. GLP-1 is a hormone that plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. By modulating the GLP-1 receptor, KN-056 aims to improve glycemic control in patients with type 2 diabetes. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes. The Type 2 Diabetes Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment. Type 2 Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market. Learn more about Type 2 Diabetes Drugs opportunities in our groundbreaking Type 2 Diabetes research and development projects @ Type 2 Diabetes Unmet Needs Type 2 Diabetes Companies Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others. Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Type 2 Diabetes Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Type 2 Diabetes treatment by visiting our website. Stay informed about how we're transforming the future of Endocrinology and Metabolic Disorders @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspectives Scope of the Type 2 Diabetes Pipeline Report Coverage- Global Type 2 Diabetes Companies- Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others. Type 2 Diabetes Pipeline Therapies- Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea and others. Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Type 2 Diabetes Pipeline on our website @ Type 2 Diabetes Emerging Drugs and Companies Table of Contents Introduction Executive Summary Type 2 Diabetes: Overview Pipeline Therapeutics Therapeutic Assessment Type 2 Diabetes– DelveInsight's Analytical Perspective Late Stage Products (Phase III) LY-3209590: Eli Lilly and Company Mid Stage Products (Phase II) HU6: Rivus Pharmaceuticals Early Stage Products (Phase I) KN056: Suzhou Alphamab Co., Ltd. Preclinical and Discovery Stage Products Drug name: Company name Inactive Products Type 2 Diabetes Key Companies Type 2 Diabetes Key Products Type 2 Diabetes- Unmet Needs Type 2 Diabetes- Market Drivers and Barriers Type 2 Diabetes- Future Perspectives and Conclusion Type 2 Diabetes Analyst Views Type 2 Diabetes Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
The Guardian
4 hours ago
- General
- The Guardian
‘Like something you see in a movie': Trump cuts stir fears of more pipeline ruptures
On a clear February evening in 2020, a smell of rotten eggs started to waft over the small town of Satartia, Mississippi, followed by a green-tinged cloud. A load roar could be heard near the highway that passes the town. Soon, nearby residents started to feel dizzy, some even passed out or lay on the ground shaking, unable to breathe. Cars, inexplicably, cut out, their drivers leaving them abandoned with the doors open on the highway. 'It was like something you see in a movie, like a zombie apocalypse,' said Jerry Briggs, a fire coordinator from nearby Warren county who was tasked with knocking on the doors of residents to get them to evacuate. Briggs and most of his colleagues were wearing breathing apparatus – one deputy who didn't do so almost collapsed and had to be carried away. Unbeknown to residents and emergency responders, a pipeline carrying carbon dioxide near Satartia had ruptured and its contents were gushing out, robbing oxygen from people and internal combustion engines in cars alike. 'We had no idea what it was,' said Briggs, who moved towards the deafening noise of the pipeline leak with a colleague, their vehicle spluttering, when they saw a car containing three men, unconscious and barely breathing. 'We just piled them on top of each other and got them out because it's debatable if they survived if we waited,' said Briggs. Ultimately, the men survived and were hospitalized along with around 45 other people. More than 200 people were evacuated. 'It was like we were all being smothered,' said Jack Willingham, director of emergency management in Yazoo county, where Satartia is situated. 'It was a pretty damn crazy day,' The near-fatal disaster was a spur to Joe Biden's administration to, for the first time, create a rule demanding a high standard of safety for the transport of carbon dioxide, a small but growing ingredient of pipelines increasingly captured from drilling sites and power plants. 'There's been a lot of concern about safety among states that permit CO2 pipelines,' said Tristan Brown, who was acting administrator of the Pipeline and Hazardous Materials and Safety Administration (PHMSA) until January. 'Stronger standards like the ones we drafted last year have the dual benefit of addressing permitting concerns while also improving safety for the public.' But shortly before the new safety regulations were due to come into force early this year, Donald Trump's new administration swiftly killed them off. A crackdown on gas leaks from pipelines was also pared back. This was followed by an exodus of senior officials from PHMSA, which oversees millions of miles of US pipelines. Five top leaders, including the head of the office of pipeline safety, have departed amid Trump's push to shrink the federal workforce. Broader staff cuts have hit the regulator, too, with PHMSA preparing for 612 employees in the coming year, down from 658 last year. There are currently 174 pipeline inspectors within this workforce, PHMSA said, which is 30% less than the number of inspectors Congress required it to have when authorizing the agency's budget in 2020. These 174 inspectors have the task of scrutinizing 3.3 million miles of pipe across the US, or around 19,000 miles per inspector. The indiscriminate nature of cuts at PHMSA 'has real world consequences in terms of undermining the basic foundations of safety for the public,' Brown said. 'A lot of expertise has left and that is worrying,' said one departed PHSMA staffer. 'The attitude from Doge [the 'department of government efficiency'] was 'your job is meaningless, go and work in the private sector.' Many people have thought they can't go through this for four years.' America has more miles of pipeline – carrying oil, propane, gas and other materials – than it does in federal highways and a federal regulator that was already overstretched. Brown said typically just one or two people have the responsibility of inspecting America's transported nuclear waste while a mere dozen staffers have to oversee more than 170 liquified natural gas plants. Each state has its own pipeline regulatory system and inspectors, too, but PHMSA is responsible for writing and enforcing national standards and is often the one to prosecute violations by any of the 3,000 businesses that currently operate pipelines. However, enforcement actions have dropped steeply under the Trump administration, which has initiated just 40 new cases this year, compared to 197 in all of 2024. 'All of these things will contribute to an increase in failures,' said Bill Caram, executive director of the nonprofit Pipeline Safety Trust. 'A strong regulator helps prevent awful tragedies and I worry we could see increased incidents now. The drop in enforcement is very troubling.' 'Everyone at PHMSA is focused on safety, there's not a lot of fat to trim, so it's hard to imagine that any reduction in force won't impact its ability to fulfill its duties. I can't believe they were ever prepared to lose so many people at once.' In some contexts, US pipelines can be viewed as very safe. A few dozen people are killed or injured each year from pipeline malfunctions but the alternatives to moving around vast quantities of toxic or flammable liquids and gases aren't risk-free. Trains can come off their tracks and spill their loads, as seen in East Palestine, Ohio, while the death toll on American roads from accidents is typically about 40,000 people a year. 'There is some super duper bad stuff that happens on the interstates,' said Briggs. Still, as Caram points out, there is a significant pipeline incident almost every day in the US, ranging from globs of oil spilling onto farmland to raging fireballs from ignited gas. Many of the pipelines snaking under Americans' feet are aging and need replacement, which can lead to failures. There has been a worrying uptick in deaths from pipeline accidents recently, too, with 30 people killed across 2023 and 2024, the most fatalities over a two-year period since 2010/11. 'This is not the time to look at deregulatory efforts, this is not time to look to save money and deregulate,' Caram said. 'The overall state of pipeline safety is really languishing with poor performance. We are not making good progress and we need stronger regulations.' A PHSMA spokesman said the agency is 'laser-focused on its mission of protecting people and the environment while unleashing American energy safely' and is in the process of appointing 'well-qualified individuals' to fill the departed senior officials. 'PHMSA has initiated more pipeline-related rule making actions since the beginning of this administration than in the entire four years of the preceding administration,' the spokesman added. 'Each of these rule makings represents an opportunity for us to promote pipeline safety by modernizing our code and encouraging innovation and the use of new technology.' The agency spokesman added that pipeline firm Denbury, now owned by Exxon, paid $2.8m in civil penalties for its regulatory violations in Satartia and agreed to take corrective actions. PHMSA also warned other operators to monitor the movement of earth and rock, to avoid a repeat of the Satartia incident where sodden soils shifted following days of rain and crunched into the pipeline, severing it. The leak was only confirmed after an emergency responder called Denbury to ascertain what happened, more than 40 minutes after the rupture, according to the PHMSA investigation. Communications between the company and the emergency services has improved since, according to both Briggs and Willingham. Denbury was contacted for comment. Today, Sartartia bears few visible scars. The pipeline is obscured from passing view by trees and blankets of kudzu, the invasive vine. The town's sleepy, tree-lined streets contains a micro town hall, as big as a tool shed, a couple of small churches, a single shuttered store. On a recent summer day a single person was outside, contentedly cutting the grass, as if that harrowing day in 2020 was a surreal dream. 'We will see how it goes with the changes, I hope it doesn't affect the safety we've worked so hard to get,' Willingham said of the cuts at PHMSA. 'We don't want a day like we had in Satartia again. In 35 years in emergency service I have seen some crazy stuff but that was a wild, wild day.'
Globe and Mail
5 hours ago
- Business
- Globe and Mail
Glioblastoma Pipeline Appears Promising With 200+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
DelveInsight's, ' Glioblastoma Pipeline Insight, 2025 ' report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Glioblastoma Pipeline Report to explore emerging therapies, key Glioblastoma Companies, and future Glioblastoma treatment landscapes @ Glioblastoma Pipeline Outlook Report Key Takeaways from the Glioblastoma Pipeline Report In July 2025, NovoCure GmbH announced a study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS). In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM). DelveInsight's Glioblastoma pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Glioblastoma treatment. The leading Glioblastoma Companies such as Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others. Promising Glioblastoma Pipeline Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others. Stay informed about the cutting-edge advancements in Glioblastoma treatments. Download for updates and be a part of the revolution in Oncology Care @ Glioblastoma Clinical Trials Assessment Glioblastoma Emerging Drugs Profile BMX-001: BioMimetix BMX-001 is a metalloporphyrin, a novel class of redox-active, small molecule. The active center is designed to mimic the center of superoxide dismutase. The primary mechanism of action is modulation of cellular signaling pathways. BMX-001 inhibits both NFkB and HIF-1a. By inhibiting these pro-survival and pro-angiogenic transcription factors, BMX-001 augments tumor killing by radiation therapy and inhibits tumor regrowth. The inhibition of NFkB blocks major components of the inflammatory cascade which simultaneously results in protection of normal tissue from radiation induced injury. BMX-001 is also being developed in head and neck cancer, anal cancer, and rectal cancer. Currently, the drug is in the Phase III stage of its development for the treatment of glioblastoma. Enzastaurin: Denovo BioPharma DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM). MDNA55: Medicenna Therapeutics, Inc. MDNA55 is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. The drug is currently under Phase II of development. MN-166: MediciNova MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses the pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 and might up-regulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves the redirection of an approved drug, ibudilast, which was first approved in Japan more than 20 years ago. Ibudilast has been prescribed to over 3.2 million patients and has a good post-marketing safety profile. Currently, the drug is in Phase II trial for the treatment of Glioblastoma. TNG456: Tango Therapeutics, Inc. TNG456 is an experimental targeted therapy developed to address the aggressive nature of glioblastoma, one of the most treatment-resistant brain tumors. Designed to inhibit key molecular pathways involved in tumor proliferation and immune evasion, TNG456 aims to enhance both direct tumor suppression and immune system activation. Preclinical data suggest potential synergy when used alongside standard-of-care therapies like radiotherapy or temozolomide. Its mechanism may involve disrupting tumor metabolism or modulating the tumor microenvironment. TNG456 represents a promising candidate in the evolving landscape of glioblastoma therapeutics, currently under investigation for efficacy and safety. The drug is currently in Phase I/II stage of its development for the treatment of glioblastoma. The Glioblastoma Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment. Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market. Learn more about Glioblastoma Drugs opportunities in our groundbreaking Glioblastoma research and development projects @ Glioblastoma Unmet Needs Glioblastoma Companies Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others. Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Glioblastoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Discover the latest advancements in Glioblastoma treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Glioblastoma Market Drivers and Barriers, and Future Perspectives Scope of the Glioblastoma Pipeline Report Coverage- Global Glioblastoma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others. Glioblastoma Pipeline Therapies- Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others. Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Glioblastoma Pipeline on our website @ Glioblastoma Emerging Drugs and Companies Table of Contents Introduction Executive Summary Glioblastoma: Overview Pipeline Therapeutics Therapeutic Assessment Glioblastoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Enzastaurin: Denovo BioPharma Mid Stage Products (Phase II) MDNA55: Medicenna Therapeutics, Inc. Early Stage Products (Phase I/II) TNG456: Tango Therapeutics, Inc. Preclinical and Discovery Stage Products RGN6024: Reglagene, Inc. Inactive Products Glioblastoma Key Companies Glioblastoma Key Products Glioblastoma- Unmet Needs Glioblastoma- Market Drivers and Barriers Glioblastoma- Future Perspectives and Conclusion Glioblastoma Analyst Views Glioblastoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
The Guardian
12 hours ago
- General
- The Guardian
‘Like something you see in a movie': Trump cuts stir fears of more pipeline ruptures
On a clear February evening in 2020, a smell of rotten eggs started to waft over the small town of Satartia, Mississippi, followed by a green-tinged cloud. A load roar could be heard near the highway that passes the town. Soon, nearby residents started to feel dizzy, some even passed out or lay on the ground shaking, unable to breathe. Cars, inexplicably, cut out, their drivers leaving them abandoned with the doors open on the highway. 'It was like something you see in a movie, like a zombie apocalypse,' said Jerry Briggs, a fire coordinator from nearby Warren county who was tasked with knocking on the doors of residents to get them to evacuate. Briggs and most of his colleagues were wearing breathing apparatus – one deputy who didn't do so almost collapsed and had to be carried away. Unbeknown to residents and emergency responders, a pipeline carrying carbon dioxide near Satartia had ruptured and its contents were gushing out, robbing oxygen from people and internal combustion engines in cars alike. 'We had no idea what it was,' said Briggs, who moved towards the deafening noise of the pipeline leak with a colleague, their vehicle spluttering, when they saw a car containing three men, unconscious and barely breathing. 'We just piled them on top of each other and got them out because it's debatable if they survived if we waited,' said Briggs. Ultimately, the men survived and were hospitalized along with around 45 other people. More than 200 people were evacuated. 'It was like we were all being smothered,' said Jack Willingham, director of emergency management in Yazoo county, where Satartia is situated. 'It was a pretty damn crazy day,' The near-fatal disaster was a spur to Joe Biden's administration to, for the first time, create a rule demanding a high standard of safety for the transport of carbon dioxide, a small but growing ingredient of pipelines increasingly captured from drilling sites and power plants. 'There's been a lot of concern about safety among states that permit CO2 pipelines,' said Tristan Brown, who was acting administrator of the Pipeline and Hazardous Materials and Safety Administration (PHMSA) until January. 'Stronger standards like the ones we drafted last year have the dual benefit of addressing permitting concerns while also improving safety for the public.' But shortly before the new safety regulations were due to come into force early this year, Donald Trump's new administration swiftly killed them off. A crackdown on gas leaks from pipelines was also pared back. This was followed by an exodus of senior officials from PHMSA, which oversees millions of miles of US pipelines. Five top leaders, including the head of the office of pipeline safety, have departed amid Trump's push to shrink the federal workforce. Broader staff cuts have hit the regulator, too, with PHMSA preparing for 612 employees in the coming year, down from 658 last year. There are currently 174 pipeline inspectors within this workforce, PHMSA said, which is 30% less than the number of inspectors Congress required it to have when authorizing the agency's budget in 2020. These 174 inspectors have the task of scrutinizing 3.3 million miles of pipe across the US, or around 19,000 miles per inspector. The indiscriminate nature of cuts at PHMSA 'has real world consequences in terms of undermining the basic foundations of safety for the public,' Brown said. 'A lot of expertise has left and that is worrying,' said one departed PHSMA staffer. 'The attitude from Doge [the 'department of government efficiency'] was 'your job is meaningless, go and work in the private sector.' Many people have thought they can't go through this for four years.' America has more miles of pipeline – carrying oil, propane, gas and other materials – than it does in federal highways and a federal regulator that was already overstretched. Brown said typically just one or two people have the responsibility of inspecting America's transported nuclear waste while a mere dozen staffers have to oversee more than 170 liquified natural gas plants. Each state has its own pipeline regulatory system and inspectors, too, but PHMSA is responsible for writing and enforcing national standards and is often the one to prosecute violations by any of the 3,000 businesses that currently operate pipelines. However, enforcement actions have dropped steeply under the Trump administration, which has initiated just 40 new cases this year, compared to 197 in all of 2024. 'All of these things will contribute to an increase in failures,' said Bill Caram, executive director of the nonprofit Pipeline Safety Trust. 'A strong regulator helps prevent awful tragedies and I worry we could see increased incidents now. The drop in enforcement is very troubling.' 'Everyone at PHMSA is focused on safety, there's not a lot of fat to trim, so it's hard to imagine that any reduction in force won't impact its ability to fulfill its duties. I can't believe they were ever prepared to lose so many people at once.' In some contexts, US pipelines can be viewed as very safe. A few dozen people are killed or injured each year from pipeline malfunctions but the alternatives to moving around vast quantities of toxic or flammable liquids and gases aren't risk-free. Trains can come off their tracks and spill their loads, as seen in East Palestine, Ohio, while the death toll on American roads from accidents is typically about 40,000 people a year. 'There is some super duper bad stuff that happens on the interstates,' said Briggs. Still, as Caram points out, there is a significant pipeline incident almost every day in the US, ranging from globs of oil spilling onto farmland to raging fireballs from ignited gas. Many of the pipelines snaking under Americans' feet are aging and need replacement, which can lead to failures. There has been a worrying uptick in deaths from pipeline accidents recently, too, with 30 people killed across 2023 and 2024, the most fatalities over a two-year period since 2010/11. 'This is not the time to look at deregulatory efforts, this is not time to look to save money and deregulate,' Caram said. 'The overall state of pipeline safety is really languishing with poor performance. We are not making good progress and we need stronger regulations.' A PHSMA spokesman said the agency is 'laser-focused on its mission of protecting people and the environment while unleashing American energy safely' and is in the process of appointing 'well-qualified individuals' to fill the departed senior officials. 'PHMSA has initiated more pipeline-related rule making actions since the beginning of this administration than in the entire four years of the preceding administration,' the spokesman added. 'Each of these rule makings represents an opportunity for us to promote pipeline safety by modernizing our code and encouraging innovation and the use of new technology.' The agency spokesman added that pipeline firm Denbury, now owned by Exxon, paid $2.8m in civil penalties for its regulatory violations in Satartia and agreed to take corrective actions. PHMSA also warned other operators to monitor the movement of earth and rock, to avoid a repeat of the Satartia incident where sodden soils shifted following days of rain and crunched into the pipeline, severing it. The leak was only confirmed after an emergency responder called Denbury to ascertain what happened, more than 40 minutes after the rupture, according to the PHMSA investigation. Communications between the company and the emergency services has improved since, according to both Briggs and Willingham. Denbury was contacted for comment. Today, Sartartia bears few visible scars. The pipeline is obscured from passing view by trees and blankets of kudzu, the invasive vine. The town's sleepy, tree-lined streets contains a micro town hall, as big as a tool shed, a couple of small churches, a single shuttered store. On a recent summer day a single person was outside, contentedly cutting the grass, as if that harrowing day in 2020 was a surreal dream. 'We will see how it goes with the changes, I hope it doesn't affect the safety we've worked so hard to get,' Willingham said of the cuts at PHMSA. 'We don't want a day like we had in Satartia again. In 35 years in emergency service I have seen some crazy stuff but that was a wild, wild day.'
Asharq Al-Awsat
2 days ago
- Politics
- Asharq Al-Awsat
'No Life Without Water': Settler Attacks Threaten West Bank Communities
From his monitoring station on a remote hill in the occupied West Bank, water operator Subhil Olayan keeps watch over a lifeline for Palestinians, the Ein Samiyah spring. So when Israeli settlers recently attacked the system of wells, pumps and pipelines he oversees, he knew the stakes, AFP reported. "There is no life without water, of course", he said, following the attack which temporarily cut off the water supply to nearby villages. The spring, which feeds the pumping station, is the main or backup water source for some 110,000 people, according to the Palestinian company that manages it -- making it one of the most vital in the West Bank, where water is in chronic short supply. The attack is one of several recent incidents in which settlers have been accused of damaging, diverting or seizing control of Palestinian water sources. "The settlers came and the first thing they did was break the pipeline. And when the pipeline is broken, we automatically have to stop pumping" water to nearby villages, some of which exclusively rely on the Ein Samiyah spring. "The water just goes into the dirt, into the ground," Olayan told AFP, adding that workers immediately fixed the damage to resume water supply. Just two days after the latest attack, Israeli settlers -- some of them armed -- splashed in pools just below the spring, while Olayan monitored water pressure and cameras from a distance. His software showed normal pressure in the pipes pulling water from the wells and the large pipe carrying water up the hill to his village of Kafr Malik. But he said maintenance teams dared not venture down to the pumping station out of fear for their safety. Since the start of the war in Gaza, deadly settler attacks on Palestinians in the West Bank have become commonplace. Last week, settlers beat a 20-year-old dual US citizen to death in the nearby village of Sinjil, prompting US ambassador Mike Huckabee to urge Israel to "aggressively investigate" the killing. - Annexation - Issa Qassis, chairman on the board of the Jerusalem Water Undertaking, which manages the Ein Samiyah spring, said he viewed the attacks as a tool for Israeli land grabs and annexation. "When you restrict water supply in certain areas, people simply move where water is available", he told AFP at a press conference. "So in a plan to move people to other lands, water is the best and fastest way", he said. Since the start of the war in Gaza, several Israeli politicians and officials have become increasingly vocal in support of annexing the West Bank, which Israel has occupied since 1967. Most prominent among them is Finance Minister Bezalel Smotrich, himself a settler, who said in November that 2025 would be the year Israel applies its sovereignty over the Palestinian territory. Qassis accused Israel's government of supporting settler attacks such as the one on Ein Samiyah. The Israeli army told AFP that soldiers were not aware of the incident in which pipes were damaged, "and therefore were unable to prevent it". The damage to Ein Samiyah's water facilities was not an isolated incident. In recent months, settlers in the nearby Jordan Valley took control of the Al-Auja spring by diverting its water from upstream, said Farhan Ghawanmeh, a representative of the Ras Ein Al Auja community. He said two other springs in the area had also recently been taken over. - Water rights - In Dura al-Qaraa, another West Bank village that uses the Ein Samiyah spring as a back-up water source, residents are also concerned about increasingly long droughts and the way Israel regulates their water rights. "For years now, no one has been planting because the water levels have decreased," said Rafeaa Qasim, a member of the village council, citing lower rainfall causing the land to be "basically abandoned". Qasim said that though water shortages in the village have existed for 30 years, residents' hands are tied in the face of this challenge. "We have no options; digging a well is not allowed", despite the presence of local water springs, he said, pointing to a well project that the UN and World Bank rejected due to Israeli law prohibiting drilling in the area. The lands chosen for drilling sit in the West Bank's Area C, which covers more than 60 percent of the territory and is under full Israeli control. Israeli NGO B'Tselem reported in 2023 that the legal system led to sharp disparities in water access within the West Bank between Palestinians and Israelis. Whereas nearly all residents of Israel and Israeli settlements have running water every day, only 36 percent of West Bank Palestinians do, the report said. In Dura al-Qaraa, Qasim fears for the future. "Each year, the water decreases and the crisis grows -- it's not getting better, it's getting worse."
